Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ethypharm-Mesalazine

More Like This

Dr. Aron Blaesi, inventor of expandable, gastroretentive fibrous dosage forms presenting dosage forms before and after expansion due to water absorption. (Photo: Business Wire)

Enzian Pharmaceutics Develops a Novel Dosage Form for Enhanced Efficacy and Reduced Side Effects of Cancer Therapies

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH

PR Newswire associated0

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Enteralia Bioscience SRL Acquires TFarma SRL

PR Newswire associated0

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

PR Newswire associated0

ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development